148 related articles for article (PubMed ID: 27743113)
1. [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].
Maaß J; Sandner D; Matthé E
Ophthalmologe; 2017 Jun; 114(6):534-542. PubMed ID: 27743113
[TBL] [Abstract][Full Text] [Related]
2. One year results of intravitreal ranibizumab monotherapy for retinal angiomatous proliferation: a comparative analysis based on disease stages.
Park YG; Roh YJ
BMC Ophthalmol; 2015 Dec; 15():182. PubMed ID: 26691185
[TBL] [Abstract][Full Text] [Related]
3. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
[TBL] [Abstract][Full Text] [Related]
4. [Retrospective investigation of anti-VEGF treatment reality and effectiveness in patients with neovascular age-related macular degeneration (AMD) in Germany: treatment reality of ranibizumab for neovascular AMD in Germany].
Ziemssen F; Eter N; Fauser S; Bopp S; Radermacher M; Hasanbasic Z; Holz FG;
Ophthalmologe; 2015 Mar; 112(3):246-54. PubMed ID: 25668709
[TBL] [Abstract][Full Text] [Related]
5. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
6. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD.
Eldem BM; Muftuoglu G; Topbaş S; Çakir M; Kadayifcilar S; Özmert E; Bahçecioğlu H; Sahin F; Sevgi S;
Acta Ophthalmol; 2015 Sep; 93(6):e458-64. PubMed ID: 25160859
[TBL] [Abstract][Full Text] [Related]
8. [Long-Term Outcome in Patients with Intravitreal Anti-VEGF Therapy for Exudative AMD].
Amstutz CA; Fleischhauer J; Zweifel S; Barthelmes D
Klin Monbl Augenheilkd; 2015 Apr; 232(4):533-7. PubMed ID: 25902115
[TBL] [Abstract][Full Text] [Related]
9. Predictors of 1-year visual outcome in OCT analysis comparing ranibizumab monotherapy versus combination therapy with PDT in exsudative age-related macular degeneration.
Weingessel B; Mihaltz K; Vécsei-Marlovits PV
Wien Klin Wochenschr; 2016 Aug; 128(15-16):560-5. PubMed ID: 25787216
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of stage III retinal angiomatous proliferation. Intravitreal ranibizumab injections].
Maier M; Perz C; Bockmaier J; Feucht N; Lohmann CP
Ophthalmologe; 2013 Dec; 110(12):1171-8. PubMed ID: 23224129
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab treatment of retinal angiomatous proliferation.
Kramann CA; Schöpfer K; Lorenz K; Zwiener I; Stoffelns BM; Pfeiffer N
Acta Ophthalmol; 2012 Aug; 90(5):487-91. PubMed ID: 20584002
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Bilateral Retinal Angiomatous Proliferation with Anti-vascular Endothelial Growth Factor: 12-Month Outcome.
Kim JM; Kim JH; Chang YS; Kim JW; Kim CG; Lee DW
Korean J Ophthalmol; 2017 Jun; 31(3):240-248. PubMed ID: 28471100
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
14. 6-Year Results of CNV Secondary to Pathological Myopia Treated with Ranibizumab.
Hefner L; Gerding H
Klin Monbl Augenheilkd; 2017 Apr; 234(4):483-486. PubMed ID: 28192841
[No Abstract] [Full Text] [Related]
15. Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration.
Regillo CD; Busbee BG; Ho AC; Ding B; Haskova Z
Am J Ophthalmol; 2015 Nov; 160(5):1014-1023.e2. PubMed ID: 26231305
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of recurrent neovascular age-related macular degeneration with ranibizumab according to the PrONTO scheme].
Wolf A; Reznicek L; Muhr J; Ulbig M; Kampik A; Haritoglou C
Ophthalmologe; 2013 Aug; 110(8):740-5. PubMed ID: 23224125
[TBL] [Abstract][Full Text] [Related]
17. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
[TBL] [Abstract][Full Text] [Related]
19. [Visual acuity and magnification requirement after ranibizumab in patients with wet age-related macular degeneration].
Kloos P; Bernasconi P; Estermann S; Bachmann B; Rutishauser Y; Thölen A
Klin Monbl Augenheilkd; 2008 May; 225(5):385-91. PubMed ID: 18454378
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
